AstraZeneca (AZN) Stock Climbs Following CEO Share Purchase and European Drug Approval Nod

Key Highlights

• CEO Pascal Soriot acquired 60,000 AstraZeneca shares at £121.02 per share on September 14, 2026
• European CHMP committee delivered a favorable assessment supporting Klygefa (gefurulimab) approval for generalised myasthenia gravis
• Phase III PREVAIL trial demonstrated Klygefa achieved its primary endpoint, with findings published in JAMA Neurology
• Upon approval, Klygefa would represent the EU’s first dual-binding nanobody C5 inhibitor for this indication
• Applications for Klygefa remain under regulatory evaluation in the US, China, and additional territories

In a significant show of confidence, AstraZeneca CEO Pascal Soriot executed a substantial personal transaction, acquiring 60,000 ordinary shares of the company at £121.02 apiece on September 14, 2026, through the London market. This investment totaled more than £7.26 million and was reported in accordance with UK market abuse disclosure requirements.

AstraZeneca PLC, AZN

This share acquisition occurred during the same week that Alexion, AstraZeneca’s dedicated rare disease division, secured significant regulatory progress across Europe.

The Committee for Medicinal Products for Human Use (CHMP) at the European Medicines Agency delivered a favorable opinion supporting the authorization of Klygefa (gefurulimab) throughout the European Union. The proposed indication covers adjunctive treatment for generalised myasthenia gravis (gMG) in adult patients who test positive for anti-acetylcholine receptor (AChR) antibodies.

Generalised myasthenia gravis represents a rare autoimmune condition characterized by debilitating muscle weakness and compromised muscle functionality. Within five major European markets (Germany, France, the UK, Italy, and Spain), approximately 82,500 individuals live with gMG, with roughly 66,000 classified as AChR-positive.

The favorable CHMP assessment drew upon data generated from the Phase III PREVAIL clinical study. These trial findings received publication in JAMA Neurology.

The study demonstrated that Klygefa successfully achieved its primary endpoint. Patients experienced a statistically meaningful enhancement from baseline in their Myasthenia Gravis Activities of Daily Living score at the 26-week mark compared to placebo. The treatment difference measured -1.6, accompanied by a p-value below 0.0001.

Notable improvement emerged as early as the first week and persisted throughout the entire 26-week study duration.

Pioneering Treatment Approach

Should the European Commission grant formal approval following the CHMP recommendation—which historically occurs in most cases—Klygefa would establish itself as the inaugural dual-binding nanobody C5 inhibitor authorized for this specific patient group across the EU.

The medication requires once-weekly administration through subcutaneous self-injection utilizing an autoinjector device, offering patients a practical at-home treatment alternative.

Clinical data indicated Klygefa demonstrated favorable tolerability. The safety characteristics aligned with previous studies involving C5 inhibitors eculizumab and ravulizumab in gMG patient populations.

Global Regulatory Status

Klygefa has received authorization in Japan and various other jurisdictions for specific adult gMG patient populations.

Marketing applications leveraging PREVAIL study data are presently undergoing regulatory assessment in the United States and China, alongside other international markets.

AZN stock traded 0.63% higher at the time of publication. Current analyst consensus rates AZN as a Buy, accompanied by a price target of £15,200.

The company maintains a market capitalization of £188.2 billion, with typical daily trading volume averaging approximately 3.3 million shares.